TVRD Tvardi Therapeutics, Inc.
Mergers ·
Cara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported.
Cara stockholders approved the share issuance for the merger with Tvardi, a reverse split range of 1-for-2 to 1-for-4, and an increase in authorized shares to 150,000,000.
Cara Therapeutics agreed on December 18, 2024 to combine with private Tvardi Therapeutics in an all-stock deal. Pre-merger Cara holders would own about 17.0% of the combined company, and the closing depends on Cara holding at least $18.0 million of net cash.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $18.0 million | $23.6 million |
| Net income (loss) | -$18.2 million | -$29.4 million |
| Cash from operations | -$23.5 million | -$18.3 million |
| Cash and equivalents | $20.7 million | $31.6 million |
| Short-term investments | $10.1 million |
Our latest story on this, dated Apr 15, 2025: "Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 15, 2025: "Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split". The story links the filing or release it is based on. Read the story.
Tvardi Therapeutics, Inc. trades under the ticker TVRD on NASDAQ.
Tvardi Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:69C.
The SEC Central Index Key (CIK) for Tvardi Therapeutics, Inc. is 1346830. Its filings are on SEC EDGAR.
13,338,943 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Tvardi Therapeutics, Inc. under United States.
Our directory classifies Tvardi Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Tvardi Therapeutics, Inc. is US1407553072.
aibio.space lists Tvardi Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Tvardi Therapeutics, Inc. reported a net loss of $18.2 million for the fiscal year ended Dec 31, 2025, and used $23.5 million of cash in operations, per its annual report to the SEC.
$18.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$15.8 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Tvardi Therapeutics, dated Apr 15, 2025: "Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split". Cara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported. Source.
Reported a financing. SEC Form 424B5. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a change of independent auditor. SEC Form 8-K (Items 2.02,4.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,5.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio